{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:33:37Z","timestamp":1789835617743,"version":"4.0.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cotrimoxazole (trimethoprim\/sulfamethoxazole) is a widely used antibiotic in ICU for the treatment of infections such as nosocomial or Pneumocystis jirovecii pneumonia. However, dosing in ICU patients is complicated by fluctuations in renal function, particularly acute kidney injury and augmented renal clearance, which affect drug elimination. This study investigated how renal function and body weight influence trimethoprim and sulfamethoxazole concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This retrospective bicentre observational study involved 116 ICU patients receiving cotrimoxazole therapy with routine therapeutic drug monitoring. The study focused on effects of estimated glomerular filtration rate (eGFR) and weight on concentrations and dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Dosing of sulfamethoxazole and trimethoprim was significantly lower in patients with eGFR &amp;lt;30\u2005mL\/min\/1.73\u2005m2, as recommended. In these patients, sulfamethoxazole concentrations were reduced, suggesting underdosing, while trimethoprim increased with worsening renal function, indicating overdose risk when eGFR &amp;lt;60\u2005mL\/min\/1.73\u2005m2. Patients on renal replacement therapy (RRT) had lower sulfamethoxazole concentrations and a reduced dose-normalized C\/D ratio, raising underdosing risk during RRT. trimethoprim was less affected by RRT, supporting dose reduction regardless of RRT status. No C\/D ratio difference was seen between obese and non-obese patients. Weight influenced sulfamethoxazole but not trimethoprim.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings underscore the need for individualized dosing in ICU patients, especially in patients with renal impairment or RRT. Current fixed-dose combination may not adequately reflect cotrimoxazole\u2019s complex pharmacokinetics in critical illness, stressing the importance of tailored strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf443","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:13:58Z","timestamp":1763558038000},"source":"Crossref","is-referenced-by-count":1,"title":["Cotrimoxazole in the intensive care unit: an impossible task for the fixed association in real life?"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3113-7301","authenticated-orcid":false,"given":"Manon","family":"Launay","sequence":"first","affiliation":[{"name":"M\u00e9decine Intensive R\u00e9animation, CHU de Saint-Etienne , Saint-Etienne ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Pina","sequence":"additional","affiliation":[{"name":"M\u00e9decine Intensive R\u00e9animation, CHU de Saint-Etienne , Saint-Etienne ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Guilhaumou","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM, INSERM, Service de Pharmacologie Clinique et Pharmacosurveillance, INS Institute Neuroscience Syst , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin","family":"Bruna","sequence":"additional","affiliation":[{"name":"M\u00e9decine Intensive R\u00e9animation, CHU de Saint-Etienne , Saint-Etienne ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Thiery","sequence":"additional","affiliation":[{"name":"M\u00e9decine Intensive R\u00e9animation, CHU de Saint-Etienne , Saint-Etienne ,","place":["France"]},{"name":"Research on Healthcare Performance RESHAPE, INSERM U1290, Universit\u00e9 Claude Bernard Lyon 1 , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8815-1580","authenticated-orcid":false,"given":"Sophie","family":"Perinel Ragey","sequence":"additional","affiliation":[{"name":"M\u00e9decine Intensive R\u00e9animation, CHU de Saint-Etienne , Saint-Etienne ,","place":["France"]},{"name":"INSERM U1059 Sainbiose, Universit\u00e9 Jean Monnet , Saint-Etienne F-42023 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"2026011413274567200_dkaf443-B1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s15010-015-0851-1","article-title":"Treatment of pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim\u2013sulfamethoxazole: lessons from an observational cohort study","volume":"44","author":"Creemers-Schild","year":"2016","journal-title":"Infection"},{"key":"2026011413274567200_dkaf443-B2","doi-asserted-by":"publisher","first-page":"e936889-1","DOI":"10.12659\/AJCR.936889","article-title":"Stenotrophomonas maltophilia infection associated with COVID-19: a case series and literature review","volume":"23","author":"Ishikawa","year":"2022","journal-title":"Am J Case Rep"},{"key":"2026011413274567200_dkaf443-B3","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/diagnostics13061106","article-title":"Upraising Stenotrophomonas maltophilia in critically ill patients: a new enemy?","volume":"13","author":"Dimopoulos","year":"2023","journal-title":"Diagnostics"},{"key":"2026011413274567200_dkaf443-B4","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/jac\/dkn301","article-title":"Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review","volume":"62","author":"Falagas","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2026011413274567200_dkaf443-B5","author":"Anon"},{"key":"2026011413274567200_dkaf443-B6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2165\/00003495-198224060-00002","article-title":"Co-trimoxazole (trimethoprim-sulfamethoxazole) an updated review of its antibacterial activity and clinical efficacy","volume":"24","author":"Wormser","year":"1982","journal-title":"Drugs"},{"key":"2026011413274567200_dkaf443-B7","doi-asserted-by":"publisher","first-page":"e01813","DOI":"10.1128\/AAC.01813-17","article-title":"Population pharmacokinetics of trimethoprim-sulfamethoxazole in infants and children","volume":"62","author":"Autmizguine","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011413274567200_dkaf443-B8","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(19)32563-2","article-title":"Acute kidney injury","volume":"394","author":"Ronco","year":"2019","journal-title":"Lancet"},{"key":"2026011413274567200_dkaf443-B9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2026011413274567200_dkaf443-B10","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1592\/phco.29.5.562","article-title":"Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis","volume":"29","author":"Heintz","year":"2009","journal-title":"Pharmacotherapy"},{"key":"2026011413274567200_dkaf443-B11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients\u2014guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique\u2014SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation\u2014SFAR)","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"2026011413274567200_dkaf443-B12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3390\/pharmaceutics14020445","article-title":"Prevalence and risk factors of augmented renal clearance: a systematic review and meta-analysis","volume":"14","author":"Hefny","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026011413274567200_dkaf443-B13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2110-5820-4-13","article-title":"Cotrimoxazole\u2014optimal dosing in the critically ill","volume":"4","author":"Brown","year":"2014","journal-title":"Ann Intensive Care"},{"key":"2026011413274567200_dkaf443-B14","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1097\/CCM.0000000000002954","article-title":"Medical versus surgical ICU obese patient outcome: a propensity-matched analysis to resolve clinical trial controversies","volume":"46","author":"De Jong","year":"2018","journal-title":"Crit Care Med"},{"key":"2026011413274567200_dkaf443-B15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/17425255.2018.1440287","article-title":"Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters","volume":"14","author":"Smit","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026011413274567200_dkaf443-B16","first-page":"RA163","article-title":"Renal consequences of obesity","volume":"16","author":"Naumnik","year":"2010","journal-title":"Med Sci Monit"},{"key":"2026011413274567200_dkaf443-B17","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1038\/nutd.2014.15","article-title":"Broad-spectrum \u03b2-lactams in obese non-critically ill patients","volume":"4","author":"Hites","year":"2014","journal-title":"Nutr & Diabetes"},{"key":"2026011413274567200_dkaf443-B18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2147\/IJNRD.S39739","article-title":"Obesity, hypertension, and chronic kidney disease","volume":"7","author":"Hall","year":"2014","journal-title":"IJNRD"},{"key":"2026011413274567200_dkaf443-B19","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3390\/antibiotics12071099","article-title":"Therapeutic drug monitoring of antimicrobials in critically ill obese patients","volume":"12","author":"Gorham","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026011413274567200_dkaf443-B20","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/ndt\/gfac282","article-title":"Trimethoprim-sulfamethoxazole and the risk of a hospital encounter with hyperkalemia: a matched population-based cohort study","volume":"38","author":"Hwang","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026011413274567200_dkaf443-B21","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.cmi.2020.02.021","article-title":"Evaluating the risk of hyperkalaemia and acute kidney injury with cotrimoxazole: a retrospective observational study","volume":"26","author":"Rajput","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2026011413274567200_dkaf443-B22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000167484","article-title":"Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis","volume":"7","author":"Nissenson","year":"1987","journal-title":"Am J Nephrol"},{"key":"2026011413274567200_dkaf443-B23","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1345\/aph.1P160","article-title":"Trimethoprim\/sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration","volume":"44","author":"Curkovic","year":"2010","journal-title":"Ann Pharmacother"},{"key":"2026011413274567200_dkaf443-B24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/2050-6511-14-19","article-title":"Cotrimoxazole plasma levels, dialyzer clearance and total removal by extended dialysis in a patient with acute kidney injury: risk of under-dosing using current dosing recommendations","volume":"14","author":"Clajus","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"2026011413274567200_dkaf443-B25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/cpt.3421","article-title":"Population pharmacokinetics of trimethoprim\/sulfamethoxazole: dosage optimization for patients with renal insufficiency or receiving continuous renal replacement therapy","volume":"117","author":"Leegwater","year":"2025","journal-title":"Clin Pharma and Therapeutics"},{"key":"2026011413274567200_dkaf443-B26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000368884","article-title":"Trimethoprim and sulfamethoxazole transmembrane clearance during modeled continuous renal replacement therapy","volume":"38","author":"Kesner","year":"2014","journal-title":"Blood Purif"},{"key":"2026011413274567200_dkaf443-B27","author":"Anon"},{"key":"2026011413274567200_dkaf443-B28","author":"Anon"},{"key":"2026011413274567200_dkaf443-B29","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1093\/infdis\/171.5.1295","article-title":"Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related pneumocystis carinii pneumonia","volume":"171","author":"Hughes","year":"1995","journal-title":"J Infect Dis"},{"key":"2026011413274567200_dkaf443-B30","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1093\/ndt\/gfs375","article-title":"A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy","volume":"27","author":"Ad-hoc working group of ERBP","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2026011413274567200_dkaf443-B31","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf443\/66030901\/dkaf443.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/1\/dkaf443\/66030901\/dkaf443.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:27:51Z","timestamp":1768415271000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf443\/8384092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf443","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,19]]},"article-number":"dkaf443"}}